Hybio Newsroom

Advancing science. Sharing innovation.

Company milestones, scientific progress, industry perspectives, and global conversations shaping the future of peptide therapeutics.

Research · Partnership · Global progress

Featured Story

The work moving peptide science forward.

July 03, 2026Scientific Updates

Semaglutide Injection NDA for Weight Management Accepted by CDE

Hybio and Sunshine Mandi advance a chemically synthesized semaglutide program toward broader metabolic-health access.

News Archive

Browse company developments, scientific updates, industry perspectives, and upcoming events.

A landmark GLP-1 milestone connects Hybio's peptide API, finished dosage form, quality, and commercialization capabilities.

The first international shipment marks a substantive step in Hybio's global commercialization strategy.

Hybio connects with global pharmaceutical partners in Shanghai to discuss peptide APIs, formulations, and CRDMO collaboration.

A new collaboration addresses solvent recovery and waste reduction across peptide synthesis, cleavage, and purification.

The inspection result reinforces Hybio's analytical discipline, data integrity, and global quality-system readiness.

A strategic cooperation term sheet creates a framework for peptide API development, supply, and broader global collaboration.

The collaboration explores AI models, data platforms, and digital infrastructure across pharmaceutical R&D and operations.

Stay Connected

Connect with Hybio for scientific collaboration, media enquiries, and global partnership opportunities.